https://doi.org/10.55788/24c2ed5f
The microbiome has previously been associated with an enhanced response to immune checkpoint inhibitors in epithelial cancers [1,2]. A study including 10 patients with refractory melanoma and treated with immune checkpoint inhibitors showed that FMT may improve the clinical response of these patients [3]. Another study among 16 patients with refractory melanoma displayed similar results [4]. âMoreover, there is evidence that FMT may improve the response to immune checkpoint inhibitors among newly diagnosed patients with melanoma,â according to Dr Gianluca Ianiro (Agostino Gemelli University Policlinic, Italy) [5]. âHowever, all this evidence comes from studies that are not randomised-controlled trials.â
Dr Ianiro and colleagues designed the randomised-controlled TACITO trial (NCT04758507) to compare FMT with a placebo among 50 participants with mRCC already receiving pembrolizumab plus axitinib [6]. The primary endpoint was progression-free survival (PFS) at 1 year post-randomisation âWe used single donors and no antibiotic pre-treatment,â added Dr Ianiro.
The 1-year PFS rates were 66.7% and 35%, significantly favouring the active arm over the placebo arm (P=0.036). âWe did not see a difference in PFS at 2 years of follow-up,â mentioned Dr Ianiro. âThe significant difference during the active period of the trial matches very well with the biological data we have on FMT.â The preliminary data on overall survival also suggests a benefit for the FMT group over the placebo group (5/25 deceased vs 10/25). The overall response rates also favour the FMT arm (52% vs 28%). Finally, the authors did not see any adverse events related to FMT.
In summary, these findings indicate that FMT may increase the efficacy of immune checkpoint inhibitor plus VEGF tyrosine kinase inhibitor combination therapy in patients with mRCC.
- Routy B, et al. Science. 2018;359(6371):91-97.
- Gopalakrishnan V, et al. Science. 2018;359(6371):97-103.
- Baruch EN, et al. Science. 2021;371(6529):602-609.
- Davar D, et al. Science. 2021;371(6529):595-602.
- Routy B, et al. Nat Medicine. 2023;29(8):2121-2132.
- Porcari S, et al. Targeted fecal microbiota transplantation in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: preliminary results from a randomized, double-blind placebo-controlled trial (TACITO trial). LB01, UEG Week 2024, 12â15 October, Vienna, Austria.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Is faecal microbiota transplantation a viable option to treat primary C. difficile infections? Next Article
Exploring zibotentan plus dapagliflozin for cirrhosis »
« Is faecal microbiota transplantation a viable option to treat primary C. difficile infections? Next Article
Exploring zibotentan plus dapagliflozin for cirrhosis »
Table of Contents: UEGW 2024
Featured articles
Cendakimab meets primary endpoints in eosinophilic oesophagitis
IBD: New Drugs, Established Agents, and Prevention
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Moving towards the prevention of IBD
New insights into perianal fistulising CD pathogenesis may lead to new therapies
Risankizumab influences key pathogenic Th17 cells in CD
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Extending ustekinumab dosing interval does not influence drug survival in IBD
CULTIVATE: Promising signal for etrasimod in Crohnâs disease
Tamuzimod delivers promising long-term data in UC
TL1A inhibitor tulisokibart shows potential in UC
Upadacitinib associated with normalisation of HRQoL in UC
Pancreas: Improved Diagnostics and Treatment Algorithms
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Irritable Bowel Syndrome: from Guar Gum to Tradipitant
Guar gum alleviates IBS-related constipation in a randomised controlled trial
How useful is colonoscopy for constipation in young women?
Liver: Exploring New Therapeutics
Encouraging results for L-carnitine in metabolic dysfunction-associated steatotic liver disease
Other Late-breaking Studies from UEGW
TACITO: Does faecal microbiota transplantation improve survival in mRCC?
Is faecal microbiota transplantation a viable option to treat primary C. difficile infections?
Cendakimab meets primary endpoints in eosinophilic oesophagitis
Related Articles
November 28, 2024
TACITO: Does faecal microbiota transplantation improve survival in mRCC?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com